Clearmind said it is continuing enrollment for the third cohort of an FDA-approved Phase I/IIa trial of CMND-100, an oral MEAI-based candidate being studied for alcohol use disorder. Positive topline results from the second cohort have already been presented, and the company said these data showed continued safety and tolerability. Clearmind said its Data and Safety Monitoring Board reviewed the cohort data and approved proceeding to the next phase. The multinational, multicenter study is designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy in patients with moderate to severe alcohol use disorder. Recruitment for the third cohort is taking place at Yale, Johns Hopkins and Tel Aviv Sourasky Medical Center.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110907PRIMZONEFULLFEED9670039) on March 11, 2026, and is solely responsible for the information contained therein.